Background A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ)
peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being …

Importance There are limited efficacious treatments for Alzheimer disease. Objective To
assess efficacy and adverse events of donanemab, an antibody designed to clear brain …

Introduction This study explored the safety and tolerability features of donanemab
(LY3002813) in patients with mild cognitive impairment due to Alzheimer's disease (AD) or …

Amyloid-β (Aβ) plaques and aggregated tau are two core mechanisms that contribute to the
clinical deterioration of Alzheimer's disease (AD). Recently, targeted-Aβ plaque reduction …

Importance Plasma biomarkers of Alzheimer disease may be useful as minimally invasive
pharmacodynamic measures of treatment outcomes. Objective To analyze the association of …

Donanemab is an amyloid‐targeting therapy that resulted in robust amyloid plaque
reduction and slowed Alzheimer's disease (AD) progression compared with placebo in the …

Importance β-amyloid plaques and neurofibrillary tau deposits biologically define Alzheimer
disease. Objective To perform post hoc analyses of amyloid reduction after donanemab …

Availability of safe and effective treatmentsfor Alzheimer disease is an urgent challenge
given the global shift toward an older population and increased risk of mild cognitive …

Background Donanemab (LY3002813) is an IgG1 antibody directed at an N-terminal
pyroglutamate of amyloid beta epitope that is present only in brain amyloid plaques …

Background The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may
initiate or potentiate pathologic processes in Alzheimer's disease. Lecanemab, a humanized …